Chronic inflammation in people with cystic fibrosis causes damage to lung tissue that can eventually lead to respiratory failure. Researchers are trying to discover ways to dampen the exaggerated immune response that causes chronic inflammation without affecting the body's natural defenses against infection.
Site Search
People with cystic fibrosis have thick, sticky mucus that blocks passages in their lungs, making it difficult for them to breathe and predisposing them to infections. New drugs are under development that will help break up and hydrate mucus in the lungs to make it easier to clear.
Cystic fibrosis-related diabetes (CFRD) is a unique type of diabetes that is common in people with CF. Learn about research underway to improve CFRD diagnosis and treatment.
Cystic fibrosis-related diabetes (CFRD) is a unique type of diabetes that is common in people with CF. With early diagnosis and proper treatment, CFRD can be managed successfully.
People with cystic fibrosis are prone to infections because of the thick, sticky mucus that clogs their airways. We are funding research to help fight these infections.
People with cystic fibrosis can experience complications in the pancreas, liver, and intestines that can lead to malnutrition, constipation, liver disease, and other digestive issues — including abdominal pain and poor appetite. Learn about research underway to address digestive system issues in CF.
New Effort Will Search for Potential Therapies Targeting the Most Common Mutation of Cystic Fibrosis
Today, the Cystic Fibrosis Foundation announced that it has awarded up to $400,000 to Life Edit Therapeutics Inc. to explore the application of their unique gene editing technology in CF.
The Cystic Fibrosis Foundation is awarding up to $15.9 million in additional funding to Eloxx Pharmaceuticals Inc. to expand clinical studies of ELX-02, a potential therapy for people with CF who have nonsense mutations.
Potential treatment from Calithera Biosciences minimizes growth of germs in the lungs